If fisetin is the accessible, low-risk senolytic that everyone should consider, dasatinib + quercetin (D+Q) is the nuclear option — the most potent senolytic combination tested in humans, backed by the most advanced clinical trial data, and capable of clearing senescent cells that gentler approaches cannot touch.
The combination was pioneered by Dr. James Kirkland’s team at the Mayo Clinic. Their 2015 paper in Aging Cell demonstrated that this two-drug approach selectively killed senescent cells in vitro and in vivo, improving physical function and extending healthspan in aged mice. Since then, multiple human clinical trials have confirmed that D+Q clears senescent cells in humans — making it the first senolytic regimen validated in our species.
But D+Q is not a supplement you buy on Amazon. Dasatinib is a prescription tyrosine kinase inhibitor originally developed for leukemia. This is a pharmaceutical intervention with real side effects and real contraindications. The Enhanced Man uses it with full knowledge of the risks, proper medical oversight, and systematic bloodwork monitoring.
The Science: Why Two Drugs?
Senescent cells are not a uniform population. They arise in different tissues, from different cell types, through different senescence triggers, and they upregulate different survival pathways to resist apoptosis. No single compound efficiently kills all types of senescent cells.
Dasatinib is a multi-target tyrosine kinase inhibitor. It potently inhibits Src family kinases, BCR-ABL, ephrin receptors, and multiple other kinases that senescent cells depend on for survival. It is particularly effective against senescent adipocyte progenitor cells (fat cell precursors) — a major source of SASP-driven systemic inflammation.
Quercetin is a flavonoid that inhibits the PI3K/AKT/mTOR survival pathway, Bcl-2 family anti-apoptotic proteins, and HIF-1α-dependent metabolic adaptations. It is particularly effective against senescent endothelial cells and bone marrow stem cells.
Together, they cover complementary senolytic spectra. Dasatinib hits the targets quercetin misses, and vice versa. The combination is more effective than either drug alone by a significant margin — a true pharmacological synergy.
Human Clinical Trial Evidence
Idiopathic Pulmonary Fibrosis (2019)
The first-ever human senolytic trial treated patients with idiopathic pulmonary fibrosis — a devastating disease driven by senescent cell accumulation in the lungs. After just 3 weeks of intermittent D+Q (3 doses per week), patients showed improved 6-minute walk distance, chair-stand test performance, and several quality of life measures. The study demonstrated that D+Q was safe in a vulnerable patient population and that senolytic clearance translated to functional improvement.
Diabetic Kidney Disease (2020)
A trial in patients with diabetic kidney disease showed that just 3 days of D+Q reduced senescent cell markers in adipose tissue and skin biopsies. Circulating SASP factors decreased significantly. The treatment was well-tolerated with no serious adverse events. This trial provided direct tissue-level evidence that D+Q clears senescent cells in living humans.
Alzheimer’s Disease (Ongoing)
The SToMP-AD trial at Wake Forest is testing D+Q in early-stage Alzheimer’s patients, based on the strong preclinical evidence that senescent glia and neurons drive neuroinflammation and neurodegeneration. Preliminary safety data shows the protocol is tolerable in this population.
Frailty in Older Adults
Multiple trials are examining D+Q’s effects on physical frailty, a condition driven by senescent cell accumulation in muscle, bone, and connective tissue. Early results suggest improvements in walking speed, grip strength, and fatigue — the clinical hallmarks of biological aging.
The D+Q Protocol
Standard Senolytic Dosing
Based on the published clinical trials, the established D+Q protocol is:
Dasatinib: 100mg orally once daily
Quercetin: 1,000mg orally once daily
Duration: 3 consecutive days
Frequency: Once monthly (some protocols use once every 2-4 weeks depending on the clinical indication)
This hit-and-run approach is fundamental to senolytic strategy. You are not trying to maintain chronic drug levels. You are delivering a brief, intense pulse that overwhelms the anti-apoptotic defenses of senescent cells, kills them, and then clears the drugs from your system before significant side effects accumulate. Senescent cells take weeks to months to re-accumulate, so monthly pulses maintain clearance.
Timing and Administration
Take both drugs with a fat-containing meal. Quercetin’s oral bioavailability is poor (approximately 2% of oral dose reaches systemic circulation) and is significantly improved by co-administration with dietary fat. Dasatinib absorption is not significantly affected by food but should be taken at the same time for protocol simplicity.
Take the dose in the morning. Dasatinib can cause gastrointestinal effects that are easier to manage during waking hours.
Pre-Protocol Preparation
Before your first D+Q cycle, establish baseline bloodwork through the Enhanced Athlete Protocol bloodwork framework:
Complete blood count with differential (dasatinib can affect blood cell counts). Comprehensive metabolic panel including liver enzymes (AST, ALT) and kidney function (creatinine, BUN, GFR). Inflammatory markers: hs-CRP, IL-6. Lipid panel. Fasting insulin and HbA1c. Optional: GDF-15 as a senescence biomarker.
Side Effects and Risk Management
Dasatinib is a potent pharmaceutical and carries meaningful side effects even at the low doses and short duration used for senolytic protocols:
Gastrointestinal effects: Nausea, diarrhea, and abdominal discomfort are the most common side effects. Usually mild at the 100mg dose and resolve within 24-48 hours of the last dose. Anti-nausea medication (ondansetron 4mg) can be taken prophylactically.
Fluid retention: Dasatinib can cause peripheral edema and, rarely, pleural effusions (fluid around the lungs). At the brief 3-day senolytic dosing, this is uncommon but should be monitored — watch for unexplained shortness of breath or leg swelling in the week following treatment.
Hematological effects: Dasatinib can reduce platelet counts and white blood cell counts. At the 3-day pulse dose, clinically significant cytopenias are rare. Check CBC one week after each cycle initially to establish your individual response.
QT prolongation: Dasatinib can prolong the QT interval on ECG. Anyone with pre-existing QT prolongation, on QT-prolonging medications, or with a history of arrhythmias should have cardiology clearance before using D+Q.
Quercetin interactions: Quercetin inhibits CYP3A4 and CYP2C9 enzymes and can affect the metabolism of many medications. Review all concurrent medications with a pharmacist or physician before starting.
Contraindications
Do NOT use D+Q if you have active bleeding disorders or thrombocytopenia, severe hepatic impairment, uncontrolled heart failure or QT prolongation, are pregnant or breastfeeding, or are on anticoagulants without medical supervision (dasatinib may potentiate bleeding risk).
D+Q vs Fisetin: Choosing Your Protocol
The decision between D+Q and fisetin depends on your risk tolerance, medical access, and the severity of senescent cell burden you are addressing:
Choose fisetin if: You are under 50 with no significant chronic disease, you want a low-risk first-line senolytic, you do not have easy access to dasatinib prescriptions, or you prefer a natural compound with an excellent safety profile.
Choose D+Q if: You are over 50 with measurable signs of accelerated aging, you have conditions known to be driven by senescent cell accumulation (fibrosis, metabolic syndrome, osteoarthritis), standard senolytics have not produced measurable improvements, or you have medical supervision and are comfortable with pharmaceutical interventions.
Consider alternating: Some Enhanced Athletes use fisetin monthly and D+Q quarterly, combining the continuous gentle clearance of fisetin with the periodic deep clearance of D+Q. This is a reasonable approach that has not been formally studied but has strong mechanistic rationale.
Stacking Senolytics with Regenerative Peptides
Killing senescent cells is only half the equation. The cleared tissue needs to regenerate. This is where the Enhanced Athlete Protocol’s peptide stack becomes critical:
Post-senolytic BPC-157 + TB-500: After each D+Q pulse, run BPC-157 (250-500mcg) and TB-500 (2-5mg) for 2-4 weeks to promote tissue regeneration in the cleared zones.
Post-senolytic GHK-Cu: GHK-Cu (200-500mcg daily) drives gene expression toward youthful repair patterns in regenerating tissue.
NAD+ restoration: Ensure NMN supplementation is ongoing to fuel the sirtuins and DNA repair enzymes active in post-senolytic tissue repair.
The sequence matters: clear the zombies, then flood the tissue with regenerative signals. This clear-and-rebuild approach is the most rational framework for systemic rejuvenation available today.
Monitoring Protocol
Track your D+Q protocol through rigorous bloodwork:
One week post-cycle: CBC with differential (check for platelet or WBC drops). CMP including liver enzymes.
Monthly (between cycles): hs-CRP, IL-6 (should trend downward over 3-6 months of monthly clearance). Fasting insulin, HbA1c (improved insulin sensitivity indicates reduced adipose senescent cell burden).
Quarterly: Full Enhanced Athlete Protocol bloodwork panel. GDF-15 if available. Consider epigenetic clock testing (GrimAge, DunedinPACE) at baseline and 6-12 months to assess biological age trajectory.
For the complete bloodwork monitoring framework, see the Enhanced Athlete Protocol bloodwork guide.
The Bigger Picture
Dasatinib + quercetin represents a paradigm shift in how we approach aging. For the first time in human history, we have pharmacological tools that selectively eliminate the cells driving age-related disease — not treating symptoms, but removing causes. The clinical trials confirm it works in humans. The question is no longer whether senolytics are real. The question is who will use them and who will watch from the sidelines.
The Enhanced Man does not watch from the sidelines. He evaluates the data. He calculates the risk-benefit ratio. He implements with precision and monitors with rigor. And he combines senolytic clearance with regenerative strategies that no pharmaceutical company has thought to package together — because no pharmaceutical company thinks like the Enhanced Man.
Clear the zombies. Rebuild the tissue. Measure the results. Repeat.
For the complete Enhanced Athlete Protocol framework including peptides, supplements, recovery, and bloodwork, visit the Enhanced Athlete Protocol hub.